AngioDynamics fills new SVP business development position

TriMed Staff | | Health Imaging | Artificial Intelligence

AngioDynamics has appointed David McDonald as senior vice president of business development, a newly created position at the company.

McDonald will report directly to Eamonn Hobbs, president and CEO.

The Queensbury, N.Y.-based AngioDynamics said that he brings more than 25 years of equity research, investment management and banking experience, and has particular expertise in analyzing long-term growth.

McDonald joins AngioDynamics from Cornerstone Healthcare Advisors, an advisory and consulting services practice, which he founded in April 2005. Prior to founding Cornerstone, the company said that he spent seven years in investment banking.

 

TriMed Staff

Related Content

Mayo Clinic and Microsoft partner to advance generative AI in radiology
ACR partners to create AI foundational model assessment website
Could synthetic images replace the need for contrast?
Experts developing AI model that learns from calcium-scoring CT scans
FDA has approved over 1,000 clinical AI applications, with most aimed at radiology
Commercially available AI increases breast cancer detection by nearly 20%

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.